Join to access to all OVN content. Join for Free
Gratitude: An absolute MUST for career advancement
gratitude in professional relationships career growth for MSLs compliance and gratitude expressing appreciation methods gratitude as career advancement tool

Gratitude: An absolute MUST for career advancement


Share This Article


Summary

In this special solo episode, Tom Caravela, Founder of The Carolan Group, delves into the essential role of gratitude within professional relationships and career growth for MSLs. He discusses the compliance aspects and the benefits of integrating gratitude into daily communications, emphasizing its impact on emails and post-meeting interactions. Tom shares creative methods for expressing appreciation and highlights annual gratitude practices to make it a consistent habit. Throughout the episode, he underscores gratitude as a crucial factor for career advancement, concluding with sincere appreciation for the listeners' support.

Tom Caravela discusses why gratitude is an absolute MUST for career advancement.

In this episode we discuss:

  • Good things come from gratitude
  • Connecting to people through gratitude
  • Time is currency
  • Going the extra mile to show others you appreciate them

Click for Source
gratitude in professional relationships, career growth for MSLs, compliance and gratitude, expressing appreciation methods, gratitude as career advancement tool

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
How to Develop IDPs Individual Development Plans and Road Maps for Career Development
Partner Avatar MSL Talk: Tom Caravela, Elaine Nadeau

How to Develop IDPs Individual Development Plans and Road Maps for Career Development

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Explore OVN